Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Researchers assessed the safety and efficacy of suzetrigine, a non-opioid pain signal inhibitor, on moderate to severe acute pain from in patients with surgical and nonsurgical pain.

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid ...

PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery ...

BMO Capital Markets analyst Evan Seigerman in a note to investors said the late-stage data for Vertex’s experimental ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on ...

Vertex Pharmaceuticals on Sunday presented its pivotal Phase III data on suzetrigine, an investigational, oral, highly ...

Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating on October 17. Jessica Fye has given ...

It was called VX-548 for quite some time while it was under development. Now they’re calling it suzetrigine. And so it is—works differently than these other pain drugs out there. It could be ...

UBS has resumed coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with a buy rating, citing the company's growth potential.